报告时间：6月25日（周一）上午9点半
报告地点：生物电子学国家重点实验室三楼会议室（逸夫科技馆）
报告题目1：
Nanoformulations for cytokine sensing in neuroscience: from nanosensors toin vivodevice development
报告人：Guozhen Liu（澳大利亚新南威尔士大学）
报告题目2：Non-coding RNA and Neuroinflammation: Implications for stroke
报告人：姚红红（东南大学医学院）
Speaker：Dr. Guozhen Liu
Australian Research Council Future Fellow and Senior Lecturer at The University of New South Wales
Personal webpage:https://www.engineering.unsw.edu.au/biomedical-engineering/staff/guozhen-liu-0
https://nanobiophotounsw.wordpress.com/
Title of the talk:Nanoformulations for cytokine sensing in neuroscience: from nanosensors toin vivodevice development
Abstract:
Cytokines secreted from cells play critical roles in tissue repair, cancer development and progression. Unfortunately, probing what cells “see”, and what they secrete as they respond in real time to the surrounding signals is still a major challenge. The ultra-low concentration of cytokine (in the pM range), and extremely dynamic, transient cytokine secretion process make cytokine quantification even difficult. By integrating with nanotechnology, biosensors as the analytical devices for the detection of an analyte, that combines a biological component with a physicochemical detector, have demonstrated huge potential for cytokine sensing. In this talk, Liu will summarize her recent research highlights on development of biosensors for detection of cytokines. Firstly, Liu will discuss the cell surface immunosensor for identifying and selecting high cytokine-secreting cells. Then Liu’s talk will cover the study on the nanosensors for intracellular cytokine sensing. Finally Liu will detail the development of in vivo biological detection devices for spatially localized cytokine monitoring in moving animals.
Biography:
Liu is an ARC Future Fellow & Senior Lecturer at UNSW, leading a research team on point-of-care diagnostics and precision theranostics. Before that, Dr Liu worked as an Associate Professor at Macquarie University. Gaining her PhD degree in Chemistry in 2006 under the supervision of Prof Justin Gooding at UNSW, Dr Liu is recognised for her innovative cross-disciplinary research in the area of nanoscale analysis, nanobiotechnology, biosensors, and biomedical devices. Dr Liu conducted her postdoctoral research at CSIRO(2006-2008) and UNSW(2008-2010), respectively before she accepted a faculty position as Associate Professor at the Central China Normal University, China(2010-2015). In 2015 Dr Liu moved back to Sydney and worked as Research Fellow at ARC Centre of Excellence for Nanoscale BioPhtotnics (CNBP) before she was awarded the ARC Future Fellowship in 2016.
Besides the academic research. Dr Liu also achieved her industrial research experience by working as R&D Manager at the US based company AgaMatrix Inc. for four years(2010-2015), to develop medical devices including glucose test strips and glucose meters.Dr Liu has published 8 patents, 1 book chapter, 63 journal papers, 10 conference papers, total citations 1840 as of June 2018, h-index 26.Dr Liu has attracted more than $2M in national and international research funding since 2015.She has been invited to give talks at 8 international conferences. Dr Liu was shortlisted by Australian Georgina Sweet Award for women in quantitative biomedical science (2016). She has been awarded prestigious ARC Future Fellowship (2016); the travel grant and childcare grant for Emerging Therapeutics Summit (2016), and the Academic Excellence Award for transdisciplinary research publications at Macquarie University (2017).
姚红红个人简介
姚红红，毕业于南京医科大学药理学系，获博士学位。东南大学医学院药理学系主任、药理学科带头人、医学院副院长。获得美国NIH基金（R01/R21）、国家自然科学基金优秀青年基金，江苏省特聘教授、江苏省“双创人才”计划、东南大学特聘教授等资助。一直致力于神经炎性相关神经系统疾病的研究，取得一系列原创性研究成果，已在有重要影响的SCI学术刊物上发表论文80余篇，包括Nature Communications，Autophagy, Cell Death and Differentiation，Blood，J Neuroscience，FASEB J等本领域高水平期刊。
联系方式：东南大学医学院
江苏省南京市鼓楼区丁家桥87号
邮箱：yaohh@seu.ed
电话：025-8327255115295594393
报告题目：Non-coding RNA and Neuroinflammation: Implications for stroke
摘要：Stroke is a leading cause of death and long-term disability worldwide. Intensive research regarding neuroprotective agents designed to block one or more steps of the neuronal ischemia cascade, however, no ideal drugs have been found to yield unequivocal improvements in clinical outcomes. Currently, stroke therapies aim to establish early reperfusion through thrombolytic and/or mechanical recanalization of obstructed blood vessels. Ischemic stroke thrombolytic therapy efficacy is limited by a narrow time window and thrombolytic recombinant tissue plasminogen activator (rt-PA) side effects. Although several clinical trials aimed at identifying effective therapies have been carried out, no pharmacological therapies that protect brain tissues are available. Therefore, novel treatment approaches that may enable clinicians and researchers to overcome the aforementioned side effects and extend the therapeutic window of time for existing treatments are urgently needed.Circular RNAs (circRNAs) are highly expressed in the brain and involved in regulating physiological and pathophysiological processes and these ncRNA species can be used as potential clinical biomarkers in CNS diseases. However, the potential role of circRNAs in neuronal damage and functional recovery in acute ischemic stroke remains largely unknown. Our investigation suggests that circRNAs may serve as a novel therapeutic target for acute ischemic injury.